Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12584029 | 0.89 | AR (0.42) | ARPGR | |
| SCHEMBL1976411 | 0.89 | AR (0.42) | ARPGR | |
| SCHEMBL3529344 | 0.87 | AR (0.51) | ARPGR | |
| SCHEMBL3525283 | 0.86 | PGR (0.47) | ARPGR | |
| SCHEMBL3524398 | 0.85 | PGR (0.46) | ARPGR | |
| SCHEMBL3528206 | 0.84 | AR (0.54) | ARPGR | |
| SCHEMBL1972672 | 0.84 | AR (0.64) | ARPGR | |
| SCHEMBL1972985 | 0.83 | AR (0.47) | ARPGR | |
| SCHEMBL3527239 | 0.83 | PGR (0.45) | ARPGR | |
| SCHEMBL3523761 | 0.81 | AR (0.40) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252591-B1 | ARYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI AVENTIS (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20110053947-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
| US-20110053947-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
| US-20110053947-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | US | disclosed |
| EP-2252591-A1 | ARYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | Sanofi-Aventis (FR) | 2010-11-24 | — | — | EP | disclosed |
| US-7759366-B2 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-7759366-B2 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-7759366-B2 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| WO-2009097999-A1 | ARYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009097999-A1 | ARYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| EP-2061767-A1 | ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE | Sanofi-Aventis (FR) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008017381-A1 | ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017381-A1 | ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | GPR119, GIPR, LIPC | AR 536/4885PGR 1268/4885 |
| US-20110053947-A1 | Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof | PGC, LIPC, CEL | AR 1971/4885PGR 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.